Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04209855
Title A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRalpha) Expression (MIRASOL)
Acronym MIRASOL
Recruitment Completed
Gender female
Phase Phase III
Variant Requirements No
Sponsors ImmunoGen, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BGR | BEL | AUS


No variant requirements are available.